

Contents

- 1 Intrauterine blood transfusion *P. N. Adama van Scheltema & D. Oepkes*
- 7 Prenatal rhesus testing *T. J. Legler*
- 12 Donor associations, a key link between donors and blood centres *N. Mikkelsen*
- 17 Established ways to keep donor's interest alive *J. Ringwald*
- 24 Blood group antigens and immune responses—detailed knowledge is necessary to prevent immunization and to follow up immunized individuals *A. Husebekk, M. T. Ahlen, M. K. Killie, H. Tiller, M. Eksteen, I. L. Killie, G. Heide, J. Kjeldsen-Kragh, B. Skogen & T. B. Stuge*
- 27 Blood groups: genetics and physiology *J.-P. Carton*
- 46 Blood safety: bacterial screening of blood products *E. Wood*
- 52 Time course of vasovagal syncope with whole blood donation *P. Tomasulo, M. Bravo & H. Kamel*
- 59 Treatment of patients with haemophilia and the patients' perspective *C. Smit*
- 63 Proteomics, the red blood cell and transfusion medicine *E. M. Pasini, M. Mann & A. W. Thomas*
- 73 Occult B hepatitis – still a risk for transfusions? *C. Velati*
- 77 Essential parameters during blood donation *M. Müller-Steinhardt*
- 78 Processing of whole blood into cellular components and plasma *D. V. Devine & D. Howe*
- 83 Multicomponent apheresis *J. Zingsem*
- 88 Optimal timing and dosing of platelet transfusions *N. M. Heddle*
- 95 Good practice in plasma collection and fractionation *C. Schärer*
- 99 Documentation of quality: the Plasma Master File (PMF) *J. Dodt*
- 101 Current relevance of arbovirus infections in transfusion medicine *A. Andonov*
- 107 How do we treat? Clinical haemotherapy: platelet transfusion *H. Schrezenmeier, B. Höchsmann & M. Wiesneth*
- 114 Pathogen inactivation/reduction of platelet concentrates: turning theory into practice *B. S. Gathof, M. E. Tauszig & S. M. Picker*
- 120 Management of preoperative anaemia in patients undergoing elective surgery *L. T. Goodnough, A. Manaitis, P. Earnshaw & the NATA Consensus Development Working Group*
- 125 Current status of pathogen inactivation methods *J. P. AuBuchon*
- 134 The challenge to develop blood transfusion medicine to high standards in resource-limited countries *F. M. Moftah*
- 136 How do I collect and process stem cells? *P. Schlenke, A. Mertens & C. Ahlke*
- 141 When do I (not) release cellular products? *A. Humpe, U. Buwitt-Beckmann & M. Gramatzki*
- 148 Current standards in tissue banking *A. Pruss & H.-J. Mönig*
- 155 Bleeding complications: therapeutic strategies in haemostasis *M. Spannagl*
- 161 ROTEM and multiplate – a suitable tool for POC? *A. Pape, C. F. Weber, P. Stein & K. Zacharowski*
- 169 Volunteer safer than replacement donor blood: a myth revealed by evidence *J.-P. Allain*
- 176 Current and future aspects of HLA in transfusion medicine, transplantation and cellular therapy *W. R. Mayr*
- 179 Skills and tasks of quality manager at a blood establishment *T. Vuk*
- 184 Do I assist or supervise? Achievements of quality management implementation *A. Slopecki*
- 190 Production of standard blood components *R. Henschler, M. M. Müller, H. U. Pfeiffer, E. Seifried & W. Sireis*
- 196 'Thank you! please visit us again'. Reflecting on the donor retention literature – implications for retention practices *I. J. T. Veldhuizen*
- 201 Donor management: DOMAINE – the European perspective *W. de Kort*
- 206 Donor hemovigilance: safety as the first priority of blood donor management *R. J. Benjamin*
- 212 Genomic stability in clinical scale expanded mesenchymal stem/stromal cells *L. Sensebé & K. Tarte*
- 213 Relevance of parasite infections outside South and Central America: Chagas disease and malaria *M. Piron*
- 219 Improving blood donor screening by nucleic acid technology (NAT) *M. Schmidt & E. Seifried*

- 230 Testing strategies looking forward *C. Bianco*
- 234 Three respiratory gases and the red cell: oxygen, carbon dioxide and nitric oxide *W. (Sunny) Dzik*
- 239 Demographic changes: the impact for safe blood supply *A. Greinacher, K. Fendrich & W. Hoffmann*
- 244 Blood donor motivation: what is ethical? What works? *A. Stutzer & L. Goette*
- 249 Regulation of cell-based medicine: the European experience *P. Rebulla, T. Montemurro & R. Giordano*
- 252 Regulation of cell-based medicine – the German experience *V. Weisbach*
- 256 *Plasmodium falciparum* malaria and carbohydrate blood group evolution *C. M. Cserti-Gazdewich*
- 267 Side-effects of blood products *U. J. H. Sachs*
- 274 Management of alloimmunized patients *S. T. Nance*
- 279 Pathogen inactivation – regulators aspects *M. Heiden & R. Seitz*
- 282 Natural killer cells: alloreactive effects in hematopoietic stem cell transplantation *K. C. Hsu*
- 288 Identification of therapeutically relevant mHags and strategies for mHag-based immunotherapy after allogeneic HSCT: where do we stand? *B. Eiz-Vesper & R. Blasczyk*
- 294 Risk modelling in blood safety – review of methods, strengths and limitations *B. Custer*
- 300 The molecular definition of red cell antigens *G. Daniels*
- 303 IT & informatics in translational research: a case study *E. Bergman & R. Davis*
- 308 Current screening strategies for blood donor screening in developing countries *M. Vermeulen & R. Reddy*
- 314 Hemostasis and massive transfusion *M. Levi*
- 317 Stem cell and cord blood transplantation – state of the art *G. Bug & H. Serve*